Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 7;110:132–141. doi: 10.1016/j.antiviral.2014.07.013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Protective efficacy of immune-competent mice treated with VNA with or without MCP-1 after infection with DRV. ICR mice (groups of 10) at the age of 4–6 weeks were infected i.m. with 10 IMLD50 DRV-Mexico and then treated intravenously with RABV-negative serum (N) or RABV-antibody positive serum (Ab) with or without recombinant murine MCP-1 (25 μg/mouse, i.c.) at 5 dpi. Infected and treated mice were observed daily for 21 days and survivorship was recorded and analyzed. Asterisks indicate significant differences (^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001) between the indicated experimental groups.